Position statement on medical cannabis use in rheumatic diseaseCanadian Rheumatology Association provides guidance to ensure empathetic care and harm reduction Increased risk of serious vertebral fractures after stopping osteoporosis drug'Drug holidays' cannot be safely taken in patients treated with denosumab Erelzi, second etanercept biosimilar, now available in Canada Approved for treatment of rheumatoid arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis Finasteride might cause rare serious muscle-related adverse effects Canadian product information is being updated to note this risk Finasteride might cause rare serious muscle-related adverse effects Canadian product information is being updated to note this risk Intra-articular triamcinolone of questionable benefit for knee osteoarthritis pain Injections show cartilage volume loss and no difference in knee pain compared to saline Kevzara: new SC biologic for moderate to severe RA Second interleukin-6 antagonist for rheumatoid arthritis reaches the Canadian market. New US guidelines for managing acute and recurrent gout Outline preferred treatments for acute gout and the benefits and risks of urate-lowering therapy to prevent recurrent gout. Pharmacist–physician collaborative care preferred in inflammatory arthritis Patient satisfaction superior to traditional physician model in a rheumatology clinic. First subsequent entry biologic for etanercept reaches the Canadian market Merck’s Brenzys approved for use in rheumatoid arthritis and ankylosing spondylitis. First Previous 12 13 14 15 16 Next Last
